[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR069461A1 - Uso de melanocortinas para tratar la sensibilidad a insulina - Google Patents

Uso de melanocortinas para tratar la sensibilidad a insulina

Info

Publication number
AR069461A1
AR069461A1 ARP080104846A ARP080104846A AR069461A1 AR 069461 A1 AR069461 A1 AR 069461A1 AR P080104846 A ARP080104846 A AR P080104846A AR P080104846 A ARP080104846 A AR P080104846A AR 069461 A1 AR069461 A1 AR 069461A1
Authority
AR
Argentina
Prior art keywords
cys
arg
phe
seq
trp
Prior art date
Application number
ARP080104846A
Other languages
English (en)
Original Assignee
Univ Louisiana State
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State, Sod Conseils Rech Applic filed Critical Univ Louisiana State
Publication of AR069461A1 publication Critical patent/AR069461A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a ligandos péptidos de los receptores de melanocortina, en particular, el receptor de melanocortina 4, y como tales, son utiles en el tratamiento de trastornos sensibles a la activacion de este receptor, tales como la resistencia a la insulina. Reivindicacion 1: Uso de un agonista del receptor de melanocortina 4 caracterizado porque es para la manufactura de un medicamento util para el tratamiento de la resistencia a la insulina en un sujeto que lo necesita. Reivindicacion 2: El uso de acuerdo con la reivindicacion 1, donde dicho agonista de receptor de melanocortina 4 util para el tratamiento de la resistencia a la insulina se selecciona del grupo que consiste en: Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-b-Ala-Lys)-NH2, SEQ. ID. Ns 1; Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2, SEQ. ID. NRO,: 1; Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2, SEQ. ID. Ns 2; D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2, SEQ. ID. Ns 3; D-Phe-c(Cys-His-D-Phe-Arg-Trp-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 3; D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2, SEQ. ID. Ns 3; Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2, SEQ. ID. Ns 2; Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2, SEQ. ID. Ns 4; Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 5; Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 6; Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 6; Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 6; Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 7; Ac-Nle-c(Cys-b-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 7; Ac-NIe-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 7; Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 7; Ac-NIe-c(Cys-GIy-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 7; Ac-NIe-c(D-Cys-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(D-Cys-D-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(D-Cys-b-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(D-Cys-GIy-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 9; Ac-NIe-c(Cys-b-AIa-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 9; Ac-NIe-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 9; Ac-NIe-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 9; Ac-NIe-c(Cys-GIy-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 9; Ac-NIe-c(D-Cys-AIa-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 10; Ac-NIe-c(D-Cys-D-AIa-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 10; Ac-NIe-c(D-Cys-b-AIa-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 10; Ac-NIe-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 10; Ac-NIe-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 10; Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEC. ID. Ns 11; Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; n-butanoiI-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2 SEQ. ID. Ns 12; Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-b-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 13; Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 13; Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-AIa-Lys)-NH2, SEC. ID. Ns 13; Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 13; Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 13; Ac-NIe-c(Asp-His-D-Phe-Arg-D-Trp-D-AIa-Lys)-NH2, SEQ. ID. Ns 14; Ac-NIe-c(Asp-His-D-Phe-Arg-D-Trp-b-AIa-Lys)-NH2, SEQ. ID. Ns 14; Ac-NIe-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 14; Ac-NIe-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2, SEQ. ID. Ns 14; Ac-NIe-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2, SEQ. ID. Ns 14; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2, SEQ. ID. Ns 15; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 15; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2, SEQ. ID. Ns 15; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-b-AIa-Cys)-NH2, SEQ. ID. Ns 15; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-D-AIa-Cys)-NH2, SEQ. ID. Ns 15; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 16; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-2-NaI-Cys)-NH2, SEQ. ID. Ns 16; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-1-NaI-Cys)-NH2, SEQ. ID. Ns 16; n-butanoil-NIe-c(Cys-D-AIa-His-D-Phe-Arg-2-NaI-Cys)-NH2, SEQ. ID. Ns 17; n-butanoil-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 17; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-2-NaI-Cys)-NH2, SEQ. ID. Ns 18; Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-NaI-Cys)-NH2, SEQ. ID. Ns 18; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-BaI-Cys)-NH2, SEQ. ID. Ns 18; Ac-NIe-c(Cys-D-GIu-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 59; Ac-NIe-c(Asp-His-D-Phe-Arg-Trp-D-AIa-LYS)-NH2, SEQ. ID. Ns 19; Ac-NIe-c(Cys-D-AIa-Hs-D-2-NaI-Arg-BaI-Cys)-NH2, SEQ. ID. Ns 20; Ac-NIe-c(Pen-D-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 21; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Pen)-NH2, SEQ. ID. Ns 22; Ac-NIe-c(Pen-D-AIa-His-D-Phe-Arg-Trp-Pen)-NH2, SEQ. ID. Ns 22; D-Phe-c(Cys-His-D-Phe-hArg-Trp-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 23; D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 24; D-Phe-c(Cys-His-D-Phe-Arg-Bip-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 25; D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 24; D-Phe-c(Cys-His-D-Phe-hArg-Bip-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 26; D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 26; NIe-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2, SEQ. ID. Ns 27; Ac-NIe-c(Asp-D-AIa-His-D-Phe-Arg-Trp-Lys)-NH2, SEQ. ID. Ns 28; Ac-NIe-c(Asp-D-AIa-His-D-Phe-Arg-BaI-Lys)-NH2, SEQ. ID. Ns 28; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Pen)-OH, SEQ. ID. Ns 29; Ac-NIe-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 30; Ac-NIe-c(Cys-D-VaI-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID, Ns 30; Ac-NIe-c(Cys-D-IIe-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 30; Ac-NIe-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 30; Ac-NIe-c(Cys-D-TIe-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 30; Ac-NIe-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 30; Ac-NIe-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 31; Ac-NIe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2, SEQ. ID. Ns 32; Ac-NIe-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2, SEQ. ID. Ns 32; Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 33; Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 33; Ac-IIe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEC. ID. Ns 33; Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 33; Ac-VaI-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 33; Ac-2-NaI-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 33; NIe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 34; Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 34; Ac-NIe-c(Cys-3-PaI-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 35; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Cys)-OH SEQ. ID. Ns 36; Ac-NIe-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 37; Ac-NIe-c(Asp-His-D-2-NaI-Arg-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 38; Ac-Nle-c(Asp-Hs-D-2-NaI-Arg-Trp-b-AIa-Lys)-NH2, SEQ, ID. Ns 38; Ac-NIe-c(Cys-His-D-2-NaI-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 39; Ac-NIe-c(Cys-His-D-2-NaI-Arg-Trp-Ahx-Cys)-NH2, SEQ. ID. Ns 39; Ac-hPhe-c(Asp-His-D-2-NaI-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 40; Ac-Cha-c(Asp-His-D-2-NaI-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 40; Ac-NIe-c(Asp-Hs-D-Phe-Arg-Trp-b-AIa-Lys)-OH SEQ. ID. Ns 41; Ac-NIe-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH SEQ. ID. Ns 42; D-Phe-c(Cys-His-D-Phe-Arg-Trp-AIa-D-Cys)-Thr-OH SEQ. ID. Ns 43; D-Phe-c(Cys-His-D-Phe-Arg-Trp-b-AIa-D-Cys)-Thr-OH SEQ. ID. Ns 43; D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-thr-OH SEQ. ID. Ns 43; Ac-NIe-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH SEQ. ID. Ns 42; Ac-NIe-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH SEQ. ID. Ns 41; Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH SEQ. ID. Ns 45; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH SEQ. ID. Ns 45; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-b-AIa-Cys)-OH SEQ. ID. Ns 45; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-D-AIa-Cys)-OH SEQ. ID. Ns 45; Ac-NIe-c(Cys-D-Ala-His-D-2-NaI-Arg-Trp-Cys)-OH SEQ. ID. Ns 46; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-2-NaI-Cys)-OH SEC. ID. Ns 46; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-1-NaI-Cys)-OH SEQ. ID. Ns 46; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-BaI-Cys)-OH SEQ. ID. Ns 46; Ac-NIe-c(Pen-D-AIa-His-D-Phe-Arg-Trp-Cys)-OH SEQ. ID. Ns 47; Ac-NIe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH SEQ. ID. Ns 48; Ac-Arg-c(Cys-D-AIa-His-D-2-NaI-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 49; Ac-Arg-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 50; Ac-D-Arg-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 50; Ac-D-Arg-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Pen)-NH2, SEQ. ID. Ns 51; Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2, SEQ. ID. Ns 52; Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2, SEQ. ID. Ns 52; Ac-Arg-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Pen)-NH2, SEQ. ID. Ns 51; Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 53; Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 53; Ac-NIe-c(Cys-3-PaI-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 35; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-GIy-Cys)-NH2, SEQ. ID. N
ARP080104846A 2007-11-05 2008-11-05 Uso de melanocortinas para tratar la sensibilidad a insulina AR069461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US193307P 2007-11-05 2007-11-05

Publications (1)

Publication Number Publication Date
AR069461A1 true AR069461A1 (es) 2010-01-27

Family

ID=40626385

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104846A AR069461A1 (es) 2007-11-05 2008-11-05 Uso de melanocortinas para tratar la sensibilidad a insulina

Country Status (21)

Country Link
US (6) US9155777B2 (es)
EP (2) EP2214693B1 (es)
JP (3) JP2011502987A (es)
KR (3) KR101290623B1 (es)
CN (2) CN101980717A (es)
AR (1) AR069461A1 (es)
AU (1) AU2008325194B2 (es)
BR (1) BRPI0819188B1 (es)
CA (2) CA2704651C (es)
DK (1) DK2214693T3 (es)
ES (2) ES2555522T3 (es)
HK (3) HK1146242A1 (es)
HU (1) HUE026842T2 (es)
IL (2) IL205554A (es)
NZ (1) NZ585131A (es)
PL (1) PL2214693T3 (es)
PT (2) PT2214693E (es)
RU (1) RU2453328C2 (es)
TR (1) TR201815292T4 (es)
TW (1) TWI374030B (es)
WO (1) WO2009061411A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5250026B2 (ja) * 2007-05-25 2013-07-31 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ヒダントインで修飾したメラノコルチン受容体リガンド
AR069461A1 (es) 2007-11-05 2010-01-27 Univ Louisiana State Uso de melanocortinas para tratar la sensibilidad a insulina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
BRPI1009644B1 (pt) 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
WO2011017209A1 (en) * 2009-08-05 2011-02-10 Ipsen Pharma S.A.S. Use of melanocortins to treat dyslipidemia
HUE031856T2 (en) 2009-08-31 2017-08-28 Tensive Controls Inc Stabilized melanocortin ligands
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
EA201290295A1 (ru) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
EP2504352B1 (en) 2009-11-23 2018-11-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
MX341642B (es) 2011-06-14 2016-08-29 Ipsen Pharma Sas Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
CA2862444A1 (en) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
EP2814501A4 (en) 2012-03-13 2016-03-02 Tensive Controls Inc MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
AU2014227712B2 (en) 2013-03-15 2018-08-02 Rhythm Pharmaceuticals, Inc. Peptide compositions
ES2825076T3 (es) 2013-03-15 2021-05-14 Rhythm Pharmaceuticals Inc Composiciones farmacéuticas
US10314883B2 (en) 2015-02-13 2019-06-11 University Of Virginia Patent Foundation Compositions and methods for regulating blood pressure
WO2017019952A1 (en) 2015-07-29 2017-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating leukocyte adhesion
US10829519B2 (en) 2015-09-18 2020-11-10 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
US11124541B2 (en) * 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
US11763106B2 (en) 2018-06-05 2023-09-19 The Research Foundation For The State University Of New York Method for passive wireless channel estimation in radio frequency network and apparatus for same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
WO2024108198A2 (en) * 2022-11-18 2024-05-23 Rhythm Pharmaceuticals, Inc. Methods of treating obesity with an mc4r agonist

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
EP1322954A4 (en) 2000-09-13 2005-08-03 Eleanor Roosevelt Inst METHOD FOR TREATING INSULIN RESISTANCE IN OVERWEIGHT AND DIABETES
MXPA04011557A (es) * 2002-05-23 2005-07-05 Chiron Corp Compuestos de quinazolinona sustituida.
EP1460070B1 (en) 2003-03-20 2007-05-16 Santhera Pharmaceuticals (Schweiz) AG Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
WO2004087159A1 (en) 2003-03-26 2004-10-14 Merck & Co., Inc. Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
MXPA05011830A (es) * 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
JP2007524584A (ja) 2003-05-09 2007-08-30 ノボ　ノルディスク　アクティーゼルスカブ 肥満の治療に使用するペプチド
CN1784423A (zh) * 2003-05-09 2006-06-07 诺沃挪第克公司 用于治疗肥胖的肽
JP2006527773A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン受容体４（ｍｃ４）作用薬とその用途
WO2005102377A1 (en) * 2004-03-29 2005-11-03 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
EP1807102A2 (en) * 2004-10-29 2007-07-18 Merck & Co., Inc. Compositions and methods for the treatment of obesity and sexual dysfunction
KR20080041639A (ko) 2005-07-08 2008-05-13 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 멜라노코르틴 수용체의 리간드
EP3354273B1 (en) 2005-07-08 2021-03-24 Ipsen Pharma Melanocortin receptor ligands
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
JP5250026B2 (ja) 2007-05-25 2013-07-31 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ヒダントインで修飾したメラノコルチン受容体リガンド
WO2008156677A2 (en) * 2007-06-15 2008-12-24 Ipsen Pharma S.A.S. Cyclic peptide melanocortin receptor ligands
AR069461A1 (es) * 2007-11-05 2010-01-27 Univ Louisiana State Uso de melanocortinas para tratar la sensibilidad a insulina
WO2011017209A1 (en) 2009-08-05 2011-02-10 Ipsen Pharma S.A.S. Use of melanocortins to treat dyslipidemia

Also Published As

Publication number Publication date
EP2214693B1 (en) 2015-09-09
PL2214693T3 (pl) 2016-03-31
KR20130065725A (ko) 2013-06-19
HUE026842T2 (en) 2016-08-29
IL205554A0 (en) 2010-12-30
TWI374030B (en) 2012-10-11
IL205554A (en) 2017-01-31
KR101290623B1 (ko) 2013-08-07
PT2214693E (pt) 2015-12-07
CA2704651A1 (en) 2009-05-14
WO2009061411A3 (en) 2010-04-15
US9439943B2 (en) 2016-09-13
US20190111105A1 (en) 2019-04-18
HK1221147A1 (zh) 2017-05-26
RU2453328C2 (ru) 2012-06-20
AU2008325194A1 (en) 2009-05-14
US9827286B2 (en) 2017-11-28
CA2704651C (en) 2017-03-07
BRPI0819188A2 (pt) 2015-09-01
KR101662044B1 (ko) 2016-10-04
KR20100075680A (ko) 2010-07-02
ES2555522T3 (es) 2016-01-04
EP2214693A2 (en) 2010-08-11
NZ585131A (en) 2012-10-26
CN103316345A (zh) 2013-09-25
EP2979703B1 (en) 2018-07-18
CN101980717A (zh) 2011-02-23
IL249998B (en) 2018-07-31
US20220339239A1 (en) 2022-10-27
JP2013144690A (ja) 2013-07-25
JP2015131827A (ja) 2015-07-23
IL249998A0 (en) 2017-03-30
US20180303899A1 (en) 2018-10-25
JP5964767B2 (ja) 2016-08-03
HK1146242A1 (en) 2011-05-27
HK1184692A1 (zh) 2014-01-30
CA2952095C (en) 2020-02-18
CA2952095A1 (en) 2009-05-14
TR201815292T4 (tr) 2018-11-21
CN103316345B (zh) 2016-05-18
TW200932258A (en) 2009-08-01
EP2979703A1 (en) 2016-02-03
ES2690556T3 (es) 2018-11-21
AU2008325194B2 (en) 2012-04-19
RU2010122897A (ru) 2011-12-20
US20150366934A1 (en) 2015-12-24
BRPI0819188B1 (pt) 2021-06-22
JP2011502987A (ja) 2011-01-27
EP2214693A4 (en) 2012-04-11
US9155777B2 (en) 2015-10-13
DK2214693T3 (en) 2015-11-30
KR20150013339A (ko) 2015-02-04
PT2979703T (pt) 2018-10-31
WO2009061411A2 (en) 2009-05-14
US20160354429A1 (en) 2016-12-08
US20100311647A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
AR069461A1 (es) Uso de melanocortinas para tratar la sensibilidad a insulina
Sharp Multiple opioid receptors on immune cells modulate intracellular signaling
Chaki et al. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl) ethyl]-4-[4-(2-methoxynaphthalen-1-yl) butyl] piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor
Illes Modulation of transmitter and hormone release by multiple neuronal opioid receptors
PE20210162A1 (es) Analogos de incretina y sus usos
PE20141178A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
WO2008147556A3 (en) Melanocortin receptor ligands modified with hydantoin
CR11868A (es) Antagonistas especificos del receptor fgf-r4
DOP2010000294A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CR20130409A (es) Novedosos derivados de azabencimidazolcíclico útiles como agentes antidiabéticos
CL2011003347A1 (es) Composicion farmaceutica que comprende un conjugado, correspondiente a benzoato de hidrocodona ; y uso en el tratamiento de una enfermedad, trastorno o afeccion mediada por la union de un opioide a receptores opioides.
GT201000179A (es) "antagonistas del receptor mineralcorticoide y metodos de uso"
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
NI201200085A (es) Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina
UY31877A (es) Péptidos específicos de los receptores de melanocortina para el tratamiento de la obesidad / 669
Starnowska-Sokół et al. Novel hybrid compounds, opioid agonist+ melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of neuropathic pain
Kimura et al. Intradermal application of nociceptin increases vascular permeability in rats: the possible involvement of histamine release from mast cells
PT1988914E (pt) Combinação de análogos de somatostatina com diferente selectividade para subtipos do receptor da somatostatina humana
Jimenez-Andrade et al. Activation of peripheral galanin receptors: differential effects on nociception
Quillet et al. Identification of an N-acylated-DArg-Leu-NH2 dipeptide as a highly selective neuropeptide FF1 receptor antagonist that potently prevents opioid-induced hyperalgesia
ES2723098T3 (es) Agonistas del péptido CRHR2 y usos de los mismos
Wu et al. Original endomorphin-1 analogues exhibit good analgesic effects
Sandrini et al. Nociceptin/orphanin FQ prevents the antinociceptive action of paracetamol on the rat hot plate test
Contet et al. No evidence for G-protein-coupled epsilon receptor in the brain of triple opioid receptor knockout mouse

Legal Events

Date Code Title Description
FB Suspension of granting procedure